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Alzheimer’s disease (AD) is an age-related neurodegenerative disorder, characterized clinically by insidious onset of
memory and cognition impairment, emergence of psychiatric symptoms and behavioral disorder, and impairment
of activities of daily living (ADL). Traditional Chinese medicine (TCM) is practiced in the Chinese health care system
for more than 2,000 years. In recent years, scientists have isolated many novel compounds from herbs, some of
which improve dementia with fewer side effects than conventional drugs and are regarded as potential anti-AD
drugs. In this review, we summarize the latest research progress on TCM showing their possible role of treatment of
AD and other demented diseases and possible pharmacological actions.
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Alzheimer’s disease (AD) is an age-related neurode-
generative disorder, characterized clinically by insidious
onset of memory and cognition impairment, emergence of
psychiatric symptoms and behavioral disorder, and loss of
activities of daily living (ADL). The histopathological
hallmarks of AD include the formation of senile plaques
(SP), neurofibrillary tangles (NFTs) and the loss of neu-
rons. With the rapid increase in the aged population in re-
cent years, senile dementia has become one of the world’s
important public health issues. AD is the most common
type of senile dementia. It is estimated that the prevalence
of AD over the age of 85 may be as high as 25 ~ 50%, and
AD is increasingly being recognized as one of the most
important medical problems in the elderly. It is very im-
portant to identify novel and pharmacotherapeutic drugs
for AD. Traditional Chinese medicine (TCM) is practiced
in the Chinese health care system for more than 2,000 -
years. Many active pharmacological compounds from
Chinese herbal medicines have been identified for the
treatment of various diseases. In recent years, scientists* Correspondence: chen_sd@medmail.com.cn
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reproduction in any medium, provided the orhave isolated many novel compounds from herbs, some of
which improve dementia with fewer side effects than con-
ventional drugs and are regarded as potential anti-AD
drugs. In this review, we summarize the latest research
progress on Chinese herbal medicines showing their roles
of treatment of AD and other demented diseases and pos-
sible pharmacological actions.Huperzine A
Huperzine A (HupA) is an extract of Huperzia serrata, it
has been used for centuries in China to treat fever,
swelling, and blood disorders. HupA is a potent, revers-
ible, and selective inhibitor of acetylcholine esterase,
exhibiting rapid absorption and penetration into the
brain in animal studies, and it has been widely used in
China for the treatment of AD. HupA was reported to
reduce glutamate-induced toxicity in neurons, possibly
through modulation of glutamate-NMDA receptor inter-
action, or of the passage of Ca2+ through associated ion
channels [1]. In addition to the hypothesized reduction
in excitotoxicity, other neuroprotective and antioxidant
properties have been suggested as well [2]. A recent dis-
covery from Yang et al. verified the co-occurrence of the
beneficial effects of HupA on mitochondrial dysfunction
and memory deficits in APP/PS1 double transgenic
mice, at a time point that AChE was not inhibited [3].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nificantly ameliorate the loss of dendritic spine density
and synaptotagmin levels in the brain of APP/PS1 trans-
genic mice, and this neuroprotection was associated with
reduced amyloid plaque burden and oligomeric beta-
amyloid (Abeta) levels in the cortex and hippocampus
[4]. HupA can improve triple transgenic mice (3xTg-AD)
learning and memory in the Morris water maze and
some indicators of emotionality without inducing im-
portant adverse effects. Moreover, HupA activate protein
kinase C/mitogen-activated protein kinase pathway sig-
nalling, alpha-secretases (ADAM 10 and TACE) and in-
crease the fraction of phospho-glycogen synthase kinase
3-beta in 3xTg-AD mice [5]. And it could activate Wnt
signaling and reduce amyloidosis in APP/PS1 transgenic
mice brain [6].
In a meta-analysis of the efficacy and safety of HupA
in AD, The author searched for randomized trials com-
paring HupA with placebo in the treatment of AD. The
primary outcome measures were mini-mental state
examination (MMSE) and ADL. Data were extracted
from four randomized clinical trials and analyzed using
standard meta-analysis and meta-regression methods.
Oral administration of HupA for 8–24 weeks (300–
500 μg daily) led to significant improvements in MMSE
and ADL. Most adverse events were cholinergic in na-
ture and no serious adverse events occurred [7]. How-
ever, another study assessed the safety, tolerability, and
efficacy of HupA in mild to moderate AD in a
multicenter trial in which 210 individuals were
randomized to receive placebo (n = 70) or HupA (200 μg
BID [n = 70] or 400 μg BID [n = 70]), for at least 16 -
weeks, with 177 subjects completing the treatment
phase. This study provides evidence that HupA 200 mg
BID has no demonstrable cognitive effect in patients
with mild to moderate AD [8]. A randomized,
multicenter trial in China showed that in a 12 weeks
treatment period (400 μg/QD), HupA improved 4.6
points in cognition assessed by ADAS-Cog, 2.7 points
by MMSE and 2.4 points by ADL in comparison with
baseline data. Only mild and transient adverse events
(edema of bilateral ankles and insomnia) were observed
in 3% of huperzine treated patients. These results
indicated its safety and effective in AD treatment [9].
Gingko biloba
The Ginkgo tree is indigenous to Korea, Japan, China,
now it can be found worldwide. Extracts from Ginkgo
biloba have been used medicinally in TCM for thousands
of years to treat circulatory problems, asthma, vertigo, fa-
tigue, and tinnitus. Ginkgo biloba has been used tradition-
ally in Iran to improve memory loss associated with blood
circulation abnormalities. Recently, it has become morewidely used in the United States to treat age-related phys-
ical and cognitive disorders. The Ginkgo biloba extract
EGb 761 has shown favourable effects on cerebral circula-
tion and neuronal cell metabolism, on the muscarinic cho-
linergic system, and showed antioxidant activity [10].
EGb761 was also neuroprotective against Abeta- and NO-
induced toxicity in vitro [11], and could reduce apoptosis
both in vitro and in vivo [12]. Using hippocampal neur-
onal cultures, Shi et al. found EGb761 can block Abeta1-
42-induced Ca2+ dyshomeostasis mediated by formation
of toxic mediators such as H2O2 and PAF [13].
Treatment with Ginkgo biloba extracts attenuated
scopolamine-induced amnesia in rats, enhanced memory
retention in young and old rats and improved short-term
memory in mice [14]. The clinical efficacy of Ginkgo biloba
extracts, including EGb 761, was observed (modest
improvements in cognitive function) following administra-
tion to AD and non-AD patients in various studies [15,16].
In a 24-week randomised controlled trial, using 240 mg
once-daily preparation of Ginkgo biloba extract EGb 761
in 404 outpatients, EGb 761 can improve cognitive
functioning, neuropsychiatric symptoms and functional
abilities in AD and VaD [17]. However, in Ginkgo Evalu-
ation of Memory (GEM) study, a randomized, double-
blind, placebo-controlled clinical trial of 3069 community-
dwelling participants aged 72 to 96 years, with a median
follow-up of 6.1 years, Snitz et al. reported that the use of
G. biloba, 120 mg twice daily, did not result in less cogni-
tive decline in older adults with normal cognition or with
mild cognitive impairment [18], Which results has the
negative study and it different from the results studied be-
fore. We thought the reason is the Participants in that
study chosed are the older adults with MCI and not AD or
VD. It is apparent that G. biloba can be useful in the treat-
ment of AD symptoms, but further research is necessary to
identify appropriate dosing regimens. Moreover, the poten-
tial effects of long-term use, interactions with other
medicines, and standardization of extracts must be a
consideration.
Curcumin
Curcuma longa is a member of the ginger family indigen-
ous to South and Southeast Asia, where it is grown com-
mercially. Turmeric is derived from the rhizome (root) of
the plant, whose most important commercial application
is curry. Curcumin was isolated in 1815, initially named
diferuloylmethane. Preparations made from Curcuma
longa have been used for centuries in ayurvedic medicine
to treat a variety of ailments. These may be taken orally
for dyspepsia, liver disease, flatulence, urinary tract dis-
ease, as a “blood purifier,” or used topically for a variety of
skin ailments. In vitro and in vivo evidence has suggested
several possible mechanisms of its action relevant to AD,
such as, anti-oxidant, anti-inflammatory properties, and a
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mal studies suggest that this agent may reduce oxidative
damage and amyloid pathology in Alzheimer transgenic
mice and may modulate amyloid-induced cytopathology
or macrophage processing of amyloid [21]. In rat model of
sporadic dementia of Alzheimer’s type, curcumin can
ameliorate the cognitive deficits and neurodegeneration
[22]. In our previous studies, we found that curcumin
showed obvious inhibitory effect on the apoptosis induced
by Abeta(25–35) [23]. In another report, we also found
that curcumin suppressed activated astroglia induced by
Abeta and it might act as a PPARgamma agonist to inhibit
the inflammation in Abeta-treated astrocytes [24].
Curcumin can inhibit Abeta-induced cytotoxicity in pri-
mary prefrontal cortical neurons by MTT and TUNEL
assays. Curcumin also corrected Abeta-induced caspase-3
activation, Bcl-2 downregulation and Akt phosphorylation
[25]. In a 24-week randomized, double blind, placebo-
controlled study, curcumin was generally well-tolerated
though three subjects on curcumin withdrew due to
gastrointestinal symptoms. But the researchers were un-
able to demonstrate clinical or biochemical evidence of ef-
ficacy of curcumin in AD in this 24-week placebo-
controlled trial though preliminary data suggested limited
bioavailability of this compound [26]. However, No clinical
trials of curcumin in AD patients have been proved to be
valid, the reason that curcumin has not been a miracle
cure is that it is poorly absorbed in humans, and its use as
a treatment for AD is currently under investigation.
Salidroside
The rhizome of Rhodiola rosea L has been used in East
Asia as a tonic and anti-aging agent since ancient times.
There has been mounting evidence that the extract from
the rhizome of Rhodiola rosea L possesses significant
neuroprotective activity and antioxidative effects. Sali-
droside is one of the major compounds from the water
extracts of the rhizome of Rhodiola rosea L. In a pre-
vious study, salidroside could significantly inhibite O2
−-or
H2O2-induced neurotoxicity in rat hippocampal neu-
rons. Several in vitro studies shown that salidroside can
protect Abeta-induced oxidative damage on rat neuro-
nal PC12 cells and on SH-SY5Y human neuroblastoma
cells [27]. In a in vivo study, salidroside can protect
hippocampal neurogenesis against streptozotocin-induced
neural injury in rat [28]. In our previous studies, we found
that salidroside was able to attenuate abnormal processing
of amyloid precursor protein by decreased BACE1 protein
level and promoted the secretion of sAPPalpha in hypoxic
condition in SH-SY5Y cells [29]. However, other study
showed that salidroside has no neuroprotective effects on
neuronal cell death induced by Abeta in PC12 cells [30].
Further studies are needed to confirm the effect of
salidroside in AD treatment.Periwinkle-vinca minor (vinpocetine)
Periwinkle has historically been used to treat a wide var-
iety of diseases. It was used as a folk remedy for diabetes
in Europe for centuries. In India, juice from the leaves
was used to treat wasp stings. In Hawaii, the plant was
boiled to make a poultice to stop bleeding. In China, it
was used as an astringent, diuretic, and cough remedy.
In Central and South America, it was used as a
homemade cold remedy to ease lung congestion and
inflammation, as well as sore throats. Numerous
mechanisms of action have been proposed for
vinpocetine; it has been reported to improve cerebral
metabolism, increase glucose and oxygen consumption
by the brain, and improve brain resistance to hypoxia
[31]. A neuroprotective effect has been claimed through
blocking voltage-gated sodium channels, modulating
neurotransmitter release, and potentiating the effect of
adenosine in cytotoxic hypoxia [32]. Vinpocetine has
been reported to have a variety of actions that would
hypothetically be beneficial in AD. vinpocetine can ameli-
orate intracerebroventricular streptozotocin induced cog-
nitive dysfunction and oxidative stress[33]. Several double-
blind studies have evaluated vinpocetine for the treatment
of AD and related conditions [34]. The best of these was a
16-week double-blind placebo-controlled trial of 203
people with mild to moderate dementia, in which
vinpocetine significantly benefit the treated group [34,35].
Meta-analysis of older studies of vinpocetine in poorly
defined dementia populations concluded that there is in-
sufficient evidence to support its clinical use at this time.
Centella asiatica L
Centella asiatica leaf is an ancient Ayurvedic remedy,
which is used as a revitalizing herb that strengthens ner-
vous function and memory. It is reported to restore
youth, memory and longevity [36]. The herb is also
taken as a tonic for poor digestion and rheumatism; the
latter suggest it may have anti-inflammatory effects.
Centella asiatica is also used in TCM for combating
physical and mental exhaustion [37]. In mice, an extract
of Centella asiatica leaf was sedative, antidepressant and
showed cholinomimetic activity, which was blocked by
atropine. These results indicate that Centella asiatica
may be appropriate to treat symptoms of depression and
anxiety in AD, and may also enhance cholinergic activity
and thus, cognitive function. An aqueous extract of
Centella asiatica leaf improved learning and memory
processes in rats, and modulated dopamine, 5-
hydroxytryptamine (5-HT) and noradrenaline systems in
rat brain in vivo [38]. The triterpene asiatic acid and its
derivatives have been shown to protect cortical neurons
from glutamate-induced excitotoxicity in vitro [39]. In
the brains of APP/PS mice, Centella asiatica extract can
impact the amyloid cascade altering amyloid beta
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stress response that has been implicated in the
neurodegenerative changes that occur with AD [40]. In
an intracerebroventricular streptozotocin model of AD,
Centella asiatica extract is effective in preventing the
cognitive deficits, as well as the oxidative stress in rats
[41]. In another in vivo study, Centella asiatica extract can
significantly attenuate intracerebroventricular colchicine-
induced cognitive impairment and associated oxidative
damage in rat. Further studies are necessary to confirm
this to identify any potential relevance in AD treatment.
Melissa officinalis L
Melissa officinalis (Labiatae) leaf has been used as a medi-
cinal plant for more than 2000 years. In traditional
European medicine, Melissa officinalis was used as a
calming and strengthening remedy and to treat migraines,
melancholia, neuroses and hysteria, and the plant has
been acclaimed for promoting long life and for restoring
memory [42]. The primary monoterpenes identified in the
essential oil of Melissa officinalis include citral (geranial
and neral) [43] which is a weak inhibitor of AChE [44].
Melissa officinalis has been the subject of research
regarding its potential as sedative and anxiolytic activities
that may be appropriate to provide symptomatic relief for
behavioural problems such as agitation in AD. Other ac-
tivities of Melissa officinalis leaf extracts that may be use-
ful for AD therapy include antioxidant effects [45] and
binding to muscarinic and nicotinic receptors in vitro
[46], which suggests that favourable effects on cholinergic
function may occur in AD patients. In some studies, Me-
lissa officinalis can reduce the cognitive deficits and has a
good sedative effect in patients with AD [47]. Previous
clinical studies showed that the extract of Melissa
officinalis reduces laboratory-induced stress [48] and
might have benefits in mood improvement [49]. The use
of these herbs and formulations should be well tolerated
and adverse effects have not yet been reported. Further
studies should be conducted to compare the current ther-
apies for AD and the use of these herbal remedies in con-
trolling the symptoms of AD.
Polygala tenuifolia willd
Polygala tenuifolia (Polygalaceae) root is used in TCM as
a cardiotonic and cerebrotonic, as a sedative and
tranquillizer, and for amnesia, forgetfulness, neuritis,
nightmares and insomnia [50]. According to the Chinese
Materia Medica, the root is supposed to have a special
effect upon the will and mental powers, giving strength
of character, improving understanding, strengthening
the memory, and increasing physical powers. There have
been numerous studies regarding the reputed memory
enhancing potential of Polygala tenuifolia root. For ex-
ample, the traditional Chinese prescription DX-9386,composed of four herbs (Panax ginseng, Polygala
tenuifolia, Acorus gramineus and Poria cocos) has
shown favourable effects in relation to AD symptoms in
several animal models. Tenuifolin inhibited amyloid-beta
secretion in vivo and vitro [51]. DX-9386 improved
motor activity, reduced lipid peroxidation, ameliorated
memory impairment and prolonged the lifespan of sen-
escence accelerated mice and, ameliorated the ethanol-
and scopolamine-induced memory impairment in mice
[52,53]. Further investigations are required to clarify the
contribution of each of the four herbs in DX-9386 to the
observed pharmacological activities. GEPT, consisting of
extracts from ginseng, epimedium, polygala, and tuber
curcumae [54], has shown valuable for the treatment of
AD. In the brain of APPV717I transgenic mice, GEPT
can reduce the level of Abeta via the inhibition of
γ-secretase (presenilin-1) and the promotion of insulin-
degrading enzyme and neprilysin [55]. It can also
increases synaptophysin expression in APPV717I trans-
genic mice. [56]. Kami-utan-to (KUT), a prescription
containing 13 herbs including Polygala tenuifolia root,
is used in traditional Japanese medicine to treat psy-
choneurological diseases. KUT dose-dependently upre-
gulated choline acetyltransferase (ChAT) activity and
increased nerve growth factor (NGF) secretion in vitro,
and improved passive avoidance behaviour and induced
ChAT activity in the cerebral cortex of aged rats, and in
scopolamine-induced memory impaired rats in vivo
[44,57]. The effects on ChAT activity and NGF secretion
in vitro were not as pronounced when treated with KUT
in the absence of Polygala tenuifolia root, but Polygala
tenuifolia root extract alone did upregulate ChAT activ-
ity and increase NGF secretion in vitro. These results
suggest that Polygala tenuifolia root, particularly the
cinnamic acid derivatives, significantly contribute to the
pharmacological activities of KUT, and may explain the
reputed beneficial effects of KUT in Japanese medicine.
Salvia miltiorrhiza bung
Throughout history Salvia miltiorrhiza (Labiatae) has
been used for the treatment of a variety of medical
conditions. The dried root of Salvia miltiorrhiza was
used in folk medicine for the management of blood
disorders. It is prescribed in TCM to stabilize the heart
and calm nerves. Official indications for the root include
treatment of blood circulation disorders, insomnia, neur-
asthenia and alleviation of inflammation [58]. Salvia
miltiorrhiza root may inhibit neuronal cell death by in-
hibition of presynaptic glutamate release, and nitric
oxide (NO) formation. Other investigations indicate Sal-
via miltiorrhiza root may modify ischaemic cell changes
by modulating somatostatin, a CNS neuropeptide that
has been implicated in learning and memory [59]. The
anti-oxidant effects of Salvia miltiorrhiza root have been
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with significant antioxidant activity. Such antioxidant
compounds may be useful in AD therapy. Salvia leriifolia
Benth (Lamiaceae) extract demonstrates antioxidant
properties and cholinesterase inhibitory activity [60].
Cryptotanshinone, a compound from Salvia miltiorrhiza,
modulates amyloid precursor protein metabolism and
attenuates Abeta deposition through upregulating alpha-
secretase in vivo and in vitro [61]. Tanshinones isolated
from Salvia miltiorrhiza root have demonstrated
antiinflammatory activity in mice and were active against
5-LOX in porcine leukocytes, but were not as active as
the crude extracts. These activities need to be further
investigated for confirmation, but could be relevant in
AD therapy.
Withania somnifera (L.) Dun
Withania somnifera (Solanaceae) root (ashwagandha) is
one of the most highly regarded herbs in Ayurvedic medi-
cine and its use dates back almost 4000 years. It is classed
among the rejuvenative tonics (‘Rasayanas’). The herb is
also traditionally used to treat inflammatory conditions,
such as arthritis. Nicotine is reported to be present in
Withania somnifera root. The presence of nicotine may
explain the reputed activity of Withania somnifera in
Ayurvedic medicine, considering that nicotine has been
associated with cognitive enhancement and protection
against AD development [62,63].There have been numer-
ous studies regarding the cognitive enhancing activities of
Withania somnifera. For example some steroidal deriva-
tives that have been isolated from Withania somnifera
root are the sitoindosides IX and X, which augmented
learning acquisition and memory in both young and old
rats. The extract containing the sitoindosides VII–X and
withaferin A also reversed the ibotenic acid-induced cog-
nitive deficit and reversed the reduction in cholinergic
markers (e.g. ACh, ChAT) in rats [64]. These observations
indicate that the sitoindosides VII–X and withaferin A
could have potential in AD therapy. A root preparation of
Withania somnifera has also been shown to significantly
reduce the number of degenerating cells in the hip-
pocampal region of stressed rats, which indicates the root
extract may have potential neuroprotective effects in
neurodegenerative disorders. Withania somnifera root,
leaves and some constituents are also reported to have
antioxidant and anti-inflammatory activities, inhibition of
human acetyl cholinesterase [65] and protect the PC-12
cells from Abeta induced cell damage [66,67], which may
also be relevant in AD therapy [68].
Conclusions
The treatment of AD remains a challenge in the modern
medicine because of the pathogenesis of AD is a com-
plex process involving both genetic and environmentalfactors; therefore development of effective disease-
modifying drugs is proving to be a difficult task. These
traditional Chinese medicines are regarded as new and
promising sources of potential anti-AD drugs. These en-
couraging preclinical and clinical trials suggest that
TCM is a promising candidate for the treatment of AD.
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